Because NSCLC patients will likely receive some form of checkpoint immunotherapy (CIT) targeting PD-1/PD-L1 in the course of their treatment, we also explored the outcome of SMARCA4-mutant patients treated with CIT. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.